S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
66,000% upside on tiny biotech? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
66,000% upside on tiny biotech? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
66,000% upside on tiny biotech? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
66,000% upside on tiny biotech? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture

Cyclo Therapeutics (CYTH) Competitors

$1.75
+0.06 (+3.55%)
(As of 02/23/2024 ET)

CYTH vs. CRTX, NKGN, DYAI, TARA, INAB, ACHL, GMDA, INKT, ESLA, and PLUR

Should you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Cortexyme (CRTX), NKGen Biotech (NKGN), Dyadic International (DYAI), Protara Therapeutics (TARA), IN8bio (INAB), Achilles Therapeutics (ACHL), Gamida Cell (GMDA), MiNK Therapeutics (INKT), Estrella Immunopharma (ESLA), and Pluri (PLUR). These companies are all part of the "medical" sector.

Cyclo Therapeutics vs.

Cortexyme (NASDAQ:CRTX) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.

Cortexyme has a net margin of 0.00% compared to Cortexyme's net margin of -2,037.29%. Cyclo Therapeutics' return on equity of -70.96% beat Cortexyme's return on equity.

Company Net Margins Return on Equity Return on Assets
CortexymeN/A -70.96% -63.53%
Cyclo Therapeutics -2,037.29%-1,706.53%-418.15%

Cyclo Therapeutics has higher revenue and earnings than Cortexyme. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CortexymeN/AN/A-$89.94M-$2.97-0.45
Cyclo Therapeutics$951.81K41.80-$15.45M-$1.67-1.05

Cortexyme has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.

Cortexyme received 149 more outperform votes than Cyclo Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Cyclo Therapeutics an outperform vote while only 64.44% of users gave Cortexyme an outperform vote.

CompanyUnderperformOutperform
CortexymeOutperform Votes
154
64.44%
Underperform Votes
85
35.56%
Cyclo TherapeuticsOutperform Votes
5
71.43%
Underperform Votes
2
28.57%

Cyclo Therapeutics has a consensus target price of $4.00, indicating a potential upside of 128.57%. Given Cortexyme's higher probable upside, analysts plainly believe Cyclo Therapeutics is more favorable than Cortexyme.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cortexyme
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Cyclo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Cortexyme had 1 more articles in the media than Cyclo Therapeutics. MarketBeat recorded 1 mentions for Cortexyme and 0 mentions for Cyclo Therapeutics. Cyclo Therapeutics' average media sentiment score of 0.00 equaled Cortexyme'saverage media sentiment score.

Company Overall Sentiment
Cortexyme Neutral
Cyclo Therapeutics Neutral

63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 23.0% of Cyclo Therapeutics shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cortexyme beats Cyclo Therapeutics on 8 of the 15 factors compared between the two stocks.


Get Cyclo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYTH vs. The Competition

MetricCyclo TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$39.78M$2.31B$5.19B$7.50B
Dividend YieldN/A1.77%2.84%3.86%
P/E Ratio-1.0510.62243.2618.55
Price / Sales41.80278.453,354.26207.32
Price / CashN/A28.5899.6455.40
Price / Book25.004.094.394.60
Net Income-$15.45M$36.99M$115.30M$207.21M
7 Day Performance-0.57%-0.09%0.91%-1.07%
1 Month Performance-5.41%10.27%7.30%3.57%
1 Year Performance62.04%7.09%10.04%5.52%

Cyclo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
Cortexyme
0 of 5 stars
$1.19
-8.5%
N/A+39.8%$35.88MN/A-0.4055News Coverage
NKGN
NKGen Biotech
0 of 5 stars
$1.55
-4.3%
N/AN/A$33.93MN/A0.00N/AUpcoming Earnings
News Coverage
DYAI
Dyadic International
1.8243 of 5 stars
$1.30
-3.0%
$6.00
+361.5%
+10.4%$37.45M$2.93M-5.657News Coverage
Positive News
TARA
Protara Therapeutics
2.3048 of 5 stars
$2.89
-3.3%
$23.00
+695.8%
+24.6%$32.83MN/A-0.4725News Coverage
INAB
IN8bio
1.7891 of 5 stars
$1.20
flat
$11.00
+816.7%
-34.7%$38.39MN/A-1.0731
ACHL
Achilles Therapeutics
2.9906 of 5 stars
$0.95
-1.0%
$11.00
+1,057.9%
+21.4%$38.74MN/A-0.50234News Coverage
GMDA
Gamida Cell
1.6879 of 5 stars
$0.37
-2.7%
$5.40
+1,371.4%
-75.9%$38.75MN/A-1.22143News Coverage
INKT
MiNK Therapeutics
1.417 of 5 stars
$0.93
-1.1%
$6.50
+600.7%
-57.3%$32.02MN/A-1.2737Negative News
Gap Up
ESLA
Estrella Immunopharma
0 of 5 stars
$1.14
+2.7%
N/AN/A$40.13MN/A0.00N/APositive News
Gap Down
PLUR
Pluri
0 of 5 stars
$0.74
-7.5%
N/A-25.4%$30.70M$290,000.00-1.06123News Coverage
Gap Down

Related Companies and Tools

This page (NASDAQ:CYTH) was last updated on 2/25/2024 by MarketBeat.com Staff